Docetaxel/Ritonavir

多西他赛/利托那韦

Report date: 2025/07/17 15:35:09

Base Information

Drug NameDocetaxel/Ritonavir
Drug Alias Name利托那韦和多西他赛ModraDoc-006/Ritonavir多西他赛/利托那韦Ritonavir•Docetaxel利托那韦•多西他赛 +[19] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTubulin depolymerization inhibitorsTubulin polymerisation promotersHuman immunodeficiency virus type 1 protease inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseTubulin
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursLiver Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsDenmark +[4] 
CombinationsYes DocetaxelRitonavir
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Netherlands Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesModra Pharmaceuticals Bv
Inactive CompaniesThe Netherlands Cancer Institute
Active IndicationsProstatic Neoplasms
Inactive IndicationsMetastatic breast cancerSolid tumoursLiver Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksN/A